Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026)
Arbutus Biopharma (ABUS) posted Change in Receivables of $178.7 million for Q1 2026, up 138458.91% sequentially from $129000.0 in Q4 2025, and up 14667.32% YoY from N/an in Q1 2025.
Arbutus Biopharma (ABUS) Change in Receivables (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Change in Receivables for 14 years, with the latest figure at $178.7 million in Q1 2026.
- Quarterly Change in Receivables rose 14667.32% year-over-year to $178.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.6 million (up 18761.76% YoY) and the FY2025 annual result came in at -$1.4 million, down 317.22% from the prior year.
- Change in Receivables advanced to $178.7 million in Q1 2026 per ABUS's latest filing, from $129000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $178.7 million in Q1 2026 and troughed at -$1.2 million in Q1 2025.
- A 5-year average of $10.5 million and a median of -$120000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2026: Change in Receivables plunged 644.0% in 2024, then soared 14667.32% in 2026.
- Over 5 years, Change in Receivables stood at -$483000.0 in 2022, then advanced by 18.22% to -$395000.0 in 2023, then jumped by 302.78% to $801000.0 in 2024, then plunged by 83.9% to $129000.0 in 2025, then soared by 138458.91% to $178.7 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $178.7 million, $129000.0, and -$120000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 632,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 632,000.00 |
| Jun 30, 2026 | 632,000.00 |
| Mar 31, 2026 | 178.74 Mn |
| Mar 31, 2026 | 178.74 Mn |
| Dec 31, 2025 | 129,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Jun 30, 2025 | -157,000.00 |
| Jun 30, 2025 | -157,000.00 |
| Mar 31, 2025 | -1.23 Mn |
| Mar 31, 2025 | -1.23 Mn |
| Dec 31, 2024 | 801,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Sep 30, 2024 | -159,000.00 |
| Sep 30, 2024 | -159,000.00 |
| Jun 30, 2024 | -372,000.00 |
| Jun 30, 2024 | -372,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |